A researcher at University of Tsukuba analyzed mutation patterns in the spike protein of the SARS-CoV-2 Delta variant. Two of the seven amino acid substitutions that emerged with the Delta variant resulted from cytosine-to-guanine (C-to-G) nucleotide substitutions, a mutation type that is among the rarest observed during SARS-CoV-2 evolution. A comparison with other major variants and within-lineage viral evolution revealed that the frequency was significantly higher than expected, indicating an unusual mutational pattern in the Delta spike protein. These findings offer new insight into the evolutionary processes associated with the emergence of highly transmissible SARS-CoV-2 variants.

An Osaka Metropolitan University-led research team performed whole-genome sequencing on 18 clinical strains of M. shinjukuense collected from Japan between 2010 and 2017 to obtain insights into its intraspecies genomic diversity and structure variation. 

Diabetic cardiomyopathy (DCM), a diabetes-specific cardiovascular complication, is pathologically characterized by cardiomyocyte apoptosis, oxidative stress, inflammatory responses, and myocardial fibrosis, distinguishing it from other cardiac disorders, such as hypertension and coronary artery disease. Challenges in early diagnosis, coupled with the limited efficacy and adverse effects of current treatments, have made DCM a significant contributor to heart failure and mortality in patients with diabetes. Natural products, recognized for their diverse sources, structural variety, and multitarget therapeutic potential, have shown promise in preventing and treating DCM. Drawing on advances over the past five years, this review systematically summarizes the pharmacological effects and molecular mechanisms of natural products (e.g., flavonoids, terpenoids, phenylpropanoids, alkaloids, and polysaccharides) in the treatment of DCM, with the aim of providing a theoretical foundation for further research and drug development.

Apatinib has been shown to be efficacious in the treatment of gallbladder cancer. However, the underlying mechanisms remain unclear. This study aimed to explore pathways related to the antitumor effects of apatinib at the cellular level in gallbladder cancer.

Despite advances in computational biology and regulatory moves to reduce animal use, a coherent framework for AI-driven polypharmacology as a bridge between animal models and human drug development is still missing. The shift from "cage" to "code" brings opportunities but also unresolved issues in biological interpretation, regulation, and education. This review critically examines this transition within the 3R framework, focusing on: (i) regulatory and ethical drivers for non-animal methods, (ii) gaps left by reduced animal use, and (iii) AI's potential to reconstruct biological complexity via multi-omics and predictive modelling. The review suggests that AI-driven polypharmacology offers a scalable, ethical, and precision-oriented path forward.